Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas

Abstract

The clinical roles played by normal and altered p53 in cancer are under intensive investigation, but larger studies describing the pattern as well as the prognostic value are still needed. The aim of this study was, using tissue array (TA), to examine the overexpression of p53 protein in 774 epithelial ovarian tumour tissues from Danish women and to evaluate whether p53 tissue expression levels correlate with clinicopathological parameters and prognosis. The distribution of p53 expression levels at different stages of disease, in different histological subtypes, and the prognostic value of p53 tissue expression were examined. Overall, p53 was expressed in 24/189 (13%) low malignant potential ovarian tumours (LMP) and in 278/585 (48%) ovarian cancers (OC). No significant difference in frequency of p53 tissue expression in LMP tissue was noted with increasing tumour stage (p=0.98). By contrast, there was a significant increase in the frequency of p53 tissue expression in OC with increasing FIGO stage (p<0.00001). Multivariate Cox regression analysis found that less than 20% tissue expression of p53 was associated with longer OC disease-specific survival. Tissue p53 expression may be of prognostic value in women with OC.

LOH rather than genotypes ofTP53codon 72 is associated with disease-free survival in primary breast cancer

“…In addition, we found agreement between the recently detected distribution of the three TP53 codon 72 genotypes Arg/Arg, Pro/Pro and Arg/Pro and an earlier published distribution among Norwegian breast cancer patients [15] and Danish controls [27], the last indicating that codon 72 genotypes are not associated with risk of breast cancer development. However, the lack of association between the different codon 72 genotypes and the number of TP53 mutations found in this study is in contrast to the findings by Langerød et al who demonstrated 28.5% of patients carrying Arg/Arg of codon 72 also carried a TP53 mutation but only 3.8% of patients carrying Pro/Pro [15].…”

“…The exact same allele frequencies (0.74 and 0.26) have previously been reported in Danish controls [27]. Of the 204 breast cancer patients 116 (57%) carried Arg/Arg, 19 (9%) carried Pro/Pro and 69 (34%) carried Arg/Pro.…”

Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas

“…The frequency of the codon 72 arginine and proline alleles in our subjects was not significantly different than previous observations in control Caucasian populations (de la Calle-Martin et al, 1990;Hogdall et al, 2002;Siddique et al, 2005). The distribution of these alleles followed Hardy-Weinberg equilibrium and there was no indication that this polymorphism impacted the risk of ovarian cancer.…”

Association Between a Single Nucleotide Polymorphism in the TP53 Region and Risk of Ovarian Cancer

“…We then screened titles, abstracts, and fulltexts when required. Exclusion of the articles inconsistent with the inclusion criteria resulted in 13 papers with complete data [14][15][16][20][21][22][23][24][25][26][27][28][29] (Fig. 1).…”